A 12‐gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5‐fluorouracil or FOLFIRI

Currently, there is no marker in use in the clinical management of colon cancer to predict which patients will respond efficiently to 5‐fluorouracil (5‐FU), a common component of all cytotoxic therapies. Our aim was to develop and validate a multigene signature associated with clinical outcome from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pathol Clin Res
Main Authors: Paquet, Eric R., Cui, Jing, Davidson, David, Pietrosemoli, Natalia, Hassan, Houssein Hajj, Tsofack, Serges P., Maltais, Annie, Hallett, Michael T., Delorenzi, Mauro, Batist, Gerald, Aloyz, Raquel, Lebel, Michel
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4939880/
https://ncbi.nlm.nih.gov/pubmed/27499901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cjp2.17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados